NAD+ Reviews: What They Measure and What They Miss

Across supplement listings, clinic testimonials and forum threads, NAD+ reviews converge on a small set of themes far more reliably than they converge on a verdict. The positive reports are dominated by two things: energy that feels steadier through the afternoon rather than spiky, and mental clarity - reviewers reach for words like fog lifting more often than they describe anything physical. Sleep comes up third, and usually as an aside rather than the headline.

The negative NAD+ reviews are just as patterned. They cluster around cost, around a complete absence of any noticeable change, and - specific to the infusion route - around how the drip itself feels. Flushing, chest tightness, nausea and an urgent need to slow the drip rate are described often enough in IV reviews to count as an expected part of the experience rather than a rare event.

Notice what almost no NAD+ review contains: a measurement. Energy and clarity are the two endpoints people report most, and they are also the two most vulnerable to expectation, to the season, to a better week of sleep, and to having just spent a meaningful amount of money. A recurring theme is worth noticing. It is not evidence of effect.

The genuinely useful signal in the corpus is not the verdict. It is that nearly every positive review describes a subjective state and nearly every negative one describes an absence of a visible result - which tells you the corpus is measuring feelings, and should be read as such.

Here is the distinction that reorganises everything else. The overwhelming majority of searchable NAD+ reviews - the Amazon listings, the supplement round-ups, the Reddit threads - describe an oral capsule. And most oral products are not NAD+ at all. They are precursors: nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR), molecules the body converts into NAD+ after absorption.

That is not a technicality. NAD+ itself is a large, unstable molecule that does not survive digestion or cross into cells intact, which is precisely why the supplement industry sells precursors instead. So when a reviewer writes that NAD+ did nothing for them, the honest reading is often that an oral precursor did nothing they could perceive - a narrower claim than the one the review appears to make.

Meanwhile, the person reading those reviews is frequently weighing something else entirely: a subcutaneous injection or an IV infusion, which bypass the gut altogether. They are reading reviews of product A to decide about product B. Our NMN vs NAD+ article covers the molecular distinction properly, and the NAD+ guide covers how the routes differ.

How to tell which one you are reading

Useful NAD+ reviews name the route in the first few lines - capsule, sublingual, injection or IV - and say how long they used it for. Reviews that never specify are usually capsule reviews, because that is what is easiest to buy and easiest to review. If a review does not tell you what went into the person, it cannot tell you much about what might happen to you.

Setting the reviews aside, the published record is more coherent than the forums suggest - and more modest than the marketing.

First, the precursors do what they claim mechanically. A randomised trial of chronic nicotinamide riboside supplementation in healthy middle-aged and older adults found it was well tolerated and did measurably raise NAD+ levels.*** So the blunt forum claim that oral NAD+ products cannot raise NAD+ at all is too strong.

Second, raising NAD+ and producing a benefit you would notice are separate questions, and this is where the evidence gets honest. A 2026 systematic review and meta-analysis pooled fifteen randomised controlled trials of oral NMN, ten of which contributed to the safety analysis. It found the supplement well tolerated, with no clear increase in adverse events and no signal of liver enzyme disturbance - but it did not find broad metabolic benefits. There were no significant effects on body weight, BMI, fasting glucose, HbA1c, lipid profiles or systolic blood pressure.* A small change in diastolic blood pressure and a non-significant trend in insulin resistance were the only hints, and the authors called explicitly for larger and longer trials.

Third, a separate systematic review of NAD and NADH supplementation across ten studies and 489 participants - covering chronic fatigue syndrome, older adults, Parkinson disease and prediabetes among others - reported that supplementation was well tolerated, with the most common side effects being muscle pain, nervous system complaints, fatigue, sleep disturbance and headaches, and no serious safety signal.** It also concluded that further work is needed before clinical benefit can be claimed for specific conditions.

The point worth carrying away: across these trials, safety and tolerability look reassuring, and efficacy on hard, measurable endpoints does not yet look established. A page that tells you otherwise is ahead of the evidence.

Where the evidence is thinnest - and it is not where you would guess

Clinic marketing tends to imply that injected and IV NAD+ are the serious, evidence-backed versions and capsules are the consumer-grade compromise. The controlled literature does not support that ordering. As best we can establish from the published literature, oral precursors have been studied in more randomised, placebo-controlled human trials than injected or infused NAD+ has. The case for the injectable route rests largely on pharmacokinetic reasoning - it bypasses digestion, so more reaches circulation - rather than on a comparable stack of outcome trials.

We prescribe the injectable form, so state the incentive plainly and weigh the sentence accordingly: bypassing the gut is a real pharmacological advantage, and it is not the same thing as proven superior outcomes. Anyone who tells you the injection is clinically proven to outperform the capsule is describing an inference, not a trial.

Beyond the route problem, four things make individual NAD+ reviews hard to compare - and recognising them is most of the skill in reading them.

1. The reviewers started from different places

NAD+ levels decline with age, and the people most likely to perceive a change are those furthest from where they started - older, more metabolically stressed, sleeping badly. A healthy 30-year-old with good sleep has far less room to feel a difference. Both write reviews. Only one of them is answering your question.

2. The endpoints are subjective and placebo-sensitive

Energy, focus and mood are precisely the outcomes that respond most strongly to expectation. This is not a slight against reviewers - it is why placebo-controlled trials exist at all. An uncontrolled personal report of feeling sharper cannot separate the compound from the anticipation, and neither can a hundred of them stacked together.

3. Almost nobody changes one variable

People start NAD+ during a push. They are also sleeping more deliberately, drinking less, training again, or have just come off a stretch of overwork. The review credits the compound because the compound is the thing that was purchased.

4. The review pools are selected

Clinics publish testimonials they like. Supplement pages are shaped by incentives and by the people motivated enough to write. Forums skew toward strong experiences at both ends, because a mild result is not worth posting about. The quiet middle - people who felt a little better, or nothing much, and simply stopped - is the group least represented and probably the largest.

Whether NAD+ is worth it is the question almost everyone arrives with, and reviews are structurally incapable of answering it, because worth depends on your starting point, your budget and what you are trying to change - none of which a stranger's review contains.

The more answerable question is whether it is doing anything for you specifically. That requires deciding in advance what would count as a result, and writing it down before you start: how many afternoons a week you currently crash, how you would rate your sleep, how recovery feels after training. Vague expectations produce vague verdicts, which is the single most common failure mode in the review corpus.

Then hold the other variables as still as you reasonably can for a defined stretch, and check your own notes at the end rather than your memory. Memory after spending money is an unreliable narrator. This is also the honest test that no review - including this page - can run for you.

If side effects or tolerability are part of the calculation, our NAD+ side effects article covers that in more depth than a reviews page reasonably can, and NAD+ injections before and after covers what people actually report over time.

ProtocolMD's NAD+ is a compounded, injectable therapy dispensed by a licensed pharmacy after a physician evaluation - not a supplement, and not something you should be able to buy without one. Prescribed for energy, age-related decline or general wellness, that is an off-label use of a compounded medication which is not FDA-approved for those indications. We say all of that as an interested party, and we would rather you weigh it openly than find it in a footer.

What we think the review corpus genuinely argues for is measurement and supervision rather than enthusiasm. A physician can establish what your baseline actually looks like, identify the ordinary causes of fatigue that get misattributed to cellular ageing - thyroid, iron, sleep apnoea, mood, medication - and rule those out before anyone reaches for an injectable. A surprising share of the disappointed NAD+ reviews are written by people who had one of those instead.

That is not a sales argument for NAD+. Quite often the outcome of the evaluation is that NAD+ is not the answer for you, and hearing that is worth more than any review on the internet.

Treat NAD+ reviews as descriptions of somebody else's experience with a product that may not even be the one you are considering, then replace the question of whether it works with the more answerable question of whether it is doing anything measurable for you.